- Companies
- Peptilogics
Peptilogics Valuation, Funding & Investors
Peptilogics is valued at $420M as of October 2025.
Last Peptilogics valuation
$420M
Series B · Oct 2025
Last Peptilogics funding round
$78M
Series B · Oct 2025
Cumulative funding Peptilogics raised
$119M
across 5 funding rounds
Key investors in Peptilogics
Founders Fund
Presight Capital
Peter Thiel
Innovation Works
Narya Capital
Beyond Ventures
About Peptilogics
Peptilogics is a Salt Lake City-headquartered clinical-stage biotech developing peptide therapeutics via its IPC platform. This computational system explores novel chemical spaces to design scalable, biologically active peptides. Lead candidate PLG0206 targets prosthetic joint infections, holding FDA Orphan Drug and QIDP designations. The firm advances additional programs in anti-infectives and partnered oncology indications.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Valuation
$420M (Oct 2025)
Peptilogics Valuation
Peptilogics is currently valued at $420M, based on its Series B in October 2025.
The $78M round was led by Founders Fund, Presight Capital and Thiel Bio, with participation from Beyond Ventures, AMR Action Fund and Narya Capital.
Peptilogics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Oct 2025 | Series B | $420M |
Peptilogics Funding History
Peptilogics has raised a total of $119M across 5 funding rounds.
Peptilogics' first fundraising round was a $400K seed round in January 2016. The most recent completed round was a $78M Series B in October 2025.
Peptilogics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2025 | Series B | Founders Fund (lead); Presight Capital (lead); Thiel Bio (lead); Beyond Ventures; AMR Action Fund; Narya Capital | $78M | $420M | Peptilogics, founded in 2020 and headquartered in San Francisco with operations in Pittsburgh, develops macrocyclic peptide therapeutics targeting challenging drug targets, particularly zaloganan for prosthetic joint infection (PJI) caused by antibiotic-resistant bacteria. The company raised $78 million in a Series B2 round on or around October 16, 2025, led by Presight Capital, Thiel Bio, and Founders Fund, with participation from AMR Action Fund, Narya Capital, and Beyond Ventures. This brought total equity funding to approximately $120 million, plus CARB-X grants. The $420 million valuation reflects strong investor confidence in Peptilogics' platform and pipeline. Zaloganan has QIDP, Orphan Drug, and Fast Track designations from the FDA. The funding will advance a Phase 2/3 pivotal trial starting December 2025 with 240 patients, measuring clinical failure rates and health economics like hospitalization duration. Although pre-revenue, Peptilogics employs 60-100 people and plans to accelerate product development, expand market reach, scale teams, and strengthen biotech positioning. Investors have backed successes like AbCellera and Kriya Therapeutics. The round aligns with biotech trends in innovative anti-infectives amid rising PJI burdens on healthcare systems. |
| Dec 2020 | Series B | Presight Capital (lead); Peter Thiel; Founders Fund | $35M | - | Peptilogics, a Pittsburgh-based biotech company founded around 2016-2017, develops a proprietary computational peptide drug design and discovery platform focused on macrocyclic peptides for challenging drug targets. The company closed a $35.4 million Series B financing on December 21, 2020, led by Presight Capital, with participation from Founders Fund and existing investor Peter Thiel. This round advanced the company's efforts in scalable rational peptide design, challenging traditional drug discovery by starting with a target drug profile and engineering novel molecules. Presight Capital, managed by Christian Angermayer and Fabian Hansen, highlighted Peptilogics' potential to lead in peptide therapeutics, positioning it among their investments in frontier biotech like AbCellera and Compass Pathways. Peter Thiel, known for early stakes in PayPal, Palantir, and biotech firms, continued support as an individual investor. The company, now headquartered in San Francisco with 60-100 employees, competes in the biotech space emphasizing technology-driven peptide innovation against players like Benchling and insitro. |
| Jun 2019 | Pre-seed | Innovation Works; Tachyon Ventures | $100K | - | - |
| Sep 2017 | Series A | Peter Thiel; BlueTree Venture Fund; Stefan Roever | $6M | - | Peptilogics is a Pittsburgh-based pre-clinical stage biotechnology company developing peptide therapeutics to treat multidrug-resistant bacterial infections using its proprietary eCAP platform. The company raised $5.5 million in Series A funding on September 29, 2017, from investors including Peter Thiel, Stefan Roever, and BlueTree Ventures. The financing supports advancing its lead candidate toward an IND filing, following preclinical data demonstrating broad-spectrum efficacy against resistant bacteria and an encouraging toxicity profile. BlueTree Ventures highlighted the platform's in vivo efficacy and safety potential, addressing the unmet need in multidrug-resistant infections. Peptilogics appointed Sanjay Kakkar, M.D., as CEO to lead the effort. The round positions the company to rapidly establish proof of concept for its peptide-based anti-infectives. |
| Jan 2016 | Seed | - | $400K | - | - |
Who has invested in Peptilogics?
11 investors have backed Peptilogics across its funding rounds, including Founders Fund, Presight Capital, Peter Thiel, Innovation Works, Narya Capital and Beyond Ventures.
Lead investors include Founders Fund, Presight Capital and Thiel Bio.
Peptilogics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Sep 2017 | ||
| 2 | Lead | Dec 2020 | ||
| 2 | Lead | Dec 2020 | ||
| 1 | Participant | Jun 2019 | ||
| -- | 1 | Lead | Oct 2025 | |
| 1 | Participant | Sep 2017 | ||
| 1 | Participant | Jun 2019 | ||
| 1 | Participant | Oct 2025 | ||
| 1 | Participant | Oct 2025 | ||
This data is available for Pro users. Sign up to see all 11 Peptilogics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPeptilogics Competitors
Peptilogics competitors include listed companies like Ropeok Technology Group and Beijing Hanyi Innovation, and private ones like DualEntry, Jada Ai, Akur8 and AssetWatch.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $415M | - | ||
| Private | - | - | $415M | - | ||
| Private | - | - | $432M | - | ||
| Private | - | - | $437M | - | ||
| Publicly listed | $23M | ($28M) | $396M | - | ||
| Publicly listed | $28M | $5M | $493M | 13.9x |
Peptilogics Public Comps
Peptilogics is still privately-owned, but its public comps include C4 Therapeutics, Atea Pharmaceuticals, Renata, Winner Technology, Editas Medicine, Zhejiang Shouxiangu, ARS Pharmaceuticals, Artiva Biotherapeutics, Nika Pharmaceuticals and Prothena Corp..
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $36M | ($113M) | 6.2x | 7.8x | (2.0x) | - | |||
| - | ($180M) | - | - | (1.1x) | (1.1x) | |||
| $348M | $48M | 1.6x | 1.5x | 11.9x | - | |||
| $46M | ($7M) | 9.0x | - | (60.9x) | - | |||
| $41M | ($157M) | 5.5x | 7.3x | (1.4x) | (1.9x) | |||
| $95M | $30M | 3.7x | 3.8x | 11.7x | - | |||
| $84M | ($179M) | 4.3x | 3.1x | (2.0x) | - | |||
| - | ($87M) | - | - | (0.8x) | - | |||
This data is available for Pro users. Sign up to see all Peptilogics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Peptilogics
| When was Peptilogics founded? | Peptilogics was founded in 2013. |
| Where is Peptilogics headquartered? | Peptilogics is headquartered in Pittsburgh, PA, United States. |
| Is Peptilogics publicly listed? | No, Peptilogics is a private, VC-backed company. |
| What is Peptilogics' valuation? | Peptilogics was last valued at $420M in its Series B in October 2025. |
| How much funding has Peptilogics raised? | Peptilogics has raised $119M across 5 funding rounds. |
| What was Peptilogics' last funding round? | Peptilogics' last funding round was a $78M Series B in October 2025, led by Founders Fund, Presight Capital and Thiel Bio. |
| Who are Peptilogics' investors? | Peptilogics' investors include Peter Thiel, Founders Fund, Presight Capital, Innovation Works, Thiel Bio, BlueTree Venture Fund, Tachyon Ventures, Beyond Ventures, AMR Action Fund, Stefan Roever and 1 other. |
| Which companies are comparable to Peptilogics? | Companies comparable to Peptilogics include DualEntry, Jada Ai, Akur8, AssetWatch, Ropeok Technology Group and Beijing Hanyi Innovation. |
See companies similar to Peptilogics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




